BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 16675074)

  • 1. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
    Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
    Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
    Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
    J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
    Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides.
    Daftarian PM; Mansour M; Pohajdak B; Fuentes-Ortega A; Korets-Smith E; Macdonald L; Weir G; Brown RG; Kast WM
    J Transl Med; 2007 Jun; 5():26. PubMed ID: 17555571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
    Samorski R; Gissmann L; Osen W
    Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice.
    Hoffmann C; Stanke J; Kaufmann AM; Loddenkemper C; Schneider A; Cichon G
    J Immunother; 2010; 33(2):136-45. PubMed ID: 20145549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTL responses to a DNA vaccine encoding E7 gene of human papillomavirus type 16 from an Iranian isolate.
    Meshkat Z; Soleimanjahi H; Mahmoudi M; Hassan ZM; Mirshahabi H; Meshkat M; Kheirandish M
    Iran J Immunol; 2008 Jun; 5(2):82-91. PubMed ID: 18523353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein.
    Liu H; Wu BH; Rowse GJ; Emtage PC
    Clin Vaccine Immunol; 2007 Aug; 14(8):1013-23. PubMed ID: 17596433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
    Herd KA; Harvey T; Khromykh AA; Tindle RW
    Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16.
    He Z; Wlazlo AP; Kowalczyk DW; Cheng J; Xiang ZQ; Giles-Davis W; Ertl HC
    Virology; 2000 Apr; 270(1):146-61. PubMed ID: 10772987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour.
    Doan T; Herd K; Ramshaw I; Thomson S; Tindle RW
    Cancer Immunol Immunother; 2005 Feb; 54(2):157-71. PubMed ID: 15480657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
    Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
    Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.